247 related articles for article (PubMed ID: 2512041)
1. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
Bevan JS; Burke CW
Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
[TBL] [Abstract][Full Text] [Related]
2. [A study on the prolactin releasing mechanism using an in vitro perfusion system with a cell column of cultured rat anterior pituitary cells].
Kageyama J
Nihon Naibunpi Gakkai Zasshi; 1984 Oct; 60(10):1243-54. PubMed ID: 6440813
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
4. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
6. Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions.
Jaquet P; Gunz G; Grisoli F
Horm Res; 1985; 22(3):153-63. PubMed ID: 3932176
[TBL] [Abstract][Full Text] [Related]
7. Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia.
Nicoletti I; Filipponi P; Fedeli L; Sfrappini M; Gregorini G; Ambrosi F; Santeusanio F
Horm Res; 1984; 20(3):202-12. PubMed ID: 6436160
[TBL] [Abstract][Full Text] [Related]
8. A giant prolactinoma and the effect of chronic bromocriptine therapy on basal and TRH-stimulated serum prolactin levels.
Barrera CM; Ruiz AE; Banks WA
Horm Res; 1991; 35(3-4):167-9. PubMed ID: 1806471
[TBL] [Abstract][Full Text] [Related]
9. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
[TBL] [Abstract][Full Text] [Related]
10. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine.
Lei T; Bai X; Liu K; Hu W; Xue D; Jiang X
J Tongji Med Univ; 1998; 18(3):161-3. PubMed ID: 10806816
[TBL] [Abstract][Full Text] [Related]
11. Prolactin secretion from human prolactinomas perifused in vitro: effect of TRH, prostaglandin E1, theophylline, dopamine and dopamine receptor blockers.
Chihara K; Iwasaki J; Minamitani N; Kaji H; Kodama H; Fujita T; Shirataki K; Tamaki N; Matsumoto S
Acta Endocrinol (Copenh); 1984 Jan; 105(1):6-13. PubMed ID: 6421041
[TBL] [Abstract][Full Text] [Related]
12. Normal and adenomatous human pituitaries secrete thyrotropin-releasing hormone in vitro: modulation by dopamine, haloperidol, and somatostatin.
Le Dafniet M; Lefebvre P; Barret A; Mechain C; Feinstein MC; Brandi AM; Peillon F
J Clin Endocrinol Metab; 1990 Aug; 71(2):480-6. PubMed ID: 1974264
[TBL] [Abstract][Full Text] [Related]
13. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of prolactin secretion from diethylstilbestrol-induced rat prolactinoma tissue in vitro.
Maas DL; Martinson DR; Erdmann MD; Wahle JS; Hagen TC
Proc Soc Exp Biol Med; 1995 Nov; 210(2):150-5. PubMed ID: 7568285
[TBL] [Abstract][Full Text] [Related]
15. The effect of dopamine on thyrotropin-releasing hormone-induced prolactin secretion in vitro.
Fagin KD; Neill JD
Endocrinology; 1981 Dec; 109(6):1835-40. PubMed ID: 6796383
[TBL] [Abstract][Full Text] [Related]
16. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
Lloyd HM; Jacobi JM; Willgoss DA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
[TBL] [Abstract][Full Text] [Related]
17. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
19. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
20. Hyperprolactinemia after neonatal prolactin (PRL) deficiency in rats: evidence for altered anterior pituitary regulation of PRL secretion.
Shah GV; Shyr SW; Grosvenor CE; Crowley WR
Endocrinology; 1988 May; 122(5):1883-9. PubMed ID: 3129278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
